Filtered By:
Drug: Januvia

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 84 results found since Jan 2013.

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
ConclusionsThese data provide evidence that treatment with liraglutide is associated with improvement of cardiac function and functional capacity in failing post-ischemic type-2 diabetes mellitus patients.
Source: Endocrine - November 8, 2016 Category: Endocrinology Source Type: research

Novel antidiabetic drugs and cardiovascular risk: primum non nocere
Conclusions Results of safety outcome studies focused on CV events, including HF and mortality for CV causes, are not homogeneous. A critical analysis of these studies may help cardiologists and diabetes specialists to adapt their therapeutic choices to individual patients.
Source: Nutrition, Metabolism and Cardiovascular Diseases - June 15, 2016 Category: Nutrition Source Type: research

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Sitagliptin and other 'gliptins'- why prescribe them?
Authors: Doggrell SA, Dimmitt SB Abstract INTRODUCTION: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors ('gliptins'). At present, there is contradictory evidence on whether the gliptins increase hospitalizations for heart failure. Areas covered: This is an evaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in high risk cardiovascular subjects with type 2 diabetes [1]. TECOS demonstrated non-inferiority for sitagliptin over placebo for the primary ...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study
Conclusions The results showed a favorable outcome of Sitagliptin as a class on lowering CVD incidence in patients with type 2 diabetes.
Source: Acta Diabetologica - December 21, 2015 Category: Endocrinology Source Type: research

Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective
Abstract Owing to the close association of cardiovascular (CV) disease with type 2 diabetes and the uncertainty surrounding the CV safety of antidiabetes agents, in 2008 the Food and Drug Administration issued guidance for the demonstration of CV safety for new antidiabetes drugs. Recently the results from CV outcomes trials of three dipeptidyl peptidase-4 (DPP-4) inhibitors and a glucagon-like peptide-1 receptor agonist have been reported. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial, the Examination of Cardiovascular Outcomes with Alogliptin versus St...
Source: Current Diabetes Reports - September 14, 2015 Category: Endocrinology Source Type: research

Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction
Chen et al. evaluated the cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in 1,025 type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) [1]. The authors set the primary outcomes as myocardial infarction, ischemic stroke or cardiovascular death, and they conducted a one-year follow-up with use of Cox proportional hazard models. Although, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for heart failure, hazard ratios (95% confidence intervals) of sitaglipti...
Source: International Journal of Cardiology - September 14, 2015 Category: Cardiology Authors: Tomoyuki Kawada Tags: Correspondence Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial
Background: Impaired glucose tolerance is present in one third of patients with a TIA or ischemic stroke and is associated with a two-fold risk of recurrent stroke. Metformin improves glucose tolerance, but often leads to side effects.The aim of this study is to explore the feasibility, safety, and effects on glucose metabolism of metformin and sitagliptin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. We will also assess whether a slow increase in metformin dose and better support and information on this treatment will reduce the incidence of side effects in these patients.Methods/DesignThe ...
Source: Trials - August 5, 2015 Category: Journals (General) Authors: Elizabeth OseiSusanne FonvilleAdrienne ZandbergenPaul BrouwersLaus MulderHester LingsmaDiederik DippelPeter KoudstaalHeleen den Hertog Source Type: research

Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study
Abstract: The cerebrovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) with ischemic stroke remains uncertain. The aim of this study was to assess the efficacy and safety of sitagliptin in patients with T2DM with recent ischemic stroke. We analyzed data from the Taiwan National Health Insurance Research Database between March 1, 2009, and December 31, 2011. Ischemic stroke patients were identified from individuals with T2DM. Patients who received sitagliptin were compared with those who did not to evaluate the cardiovascular safety and efficacy...
Source: Medicine - July 1, 2015 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults with Impaired Glucose Tolerance.
CONCLUSION: Sitagliptin had beneficial systemic and adipose anti-inflammatory effects in cART-treated HIV+ adults with impaired glucose tolerance. Large scale, long-term studies should determine if sitagliptin reduces cardiovascular risk and events in HIV+ adults. PMID: 25938633 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - May 4, 2015 Category: Endocrinology Authors: Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE Tags: J Clin Endocrinol Metab Source Type: research

Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative–inflammatory–apoptotic pathway
Publication date: 1 April 2015 Source:Life Sciences, Volume 126 Author(s): Ayman E. El-Sahar , Marwa M. Safar , Hala F. Zaki , Amina S. Attia , Afaf A. Ain-Shoka Aims Ischemic stroke is a major macrovascular complication of diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, was recently shown to improve cognitive functions in diabetic rats; hence the present study was conducted to evaluate its protective effect against transient ischemia–reperfusion (I/R) in diabetic animals. Main methods Diabetes was induced by streptozotocin (40mg/kg). Six weeks later, cerebral I/R was induced by bicommon carotid o...
Source: Life Sciences - March 11, 2015 Category: Biology Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research